Review
Copyright ©The Author(s) 2017.
World J Exp Med. Feb 20, 2017; 7(1): 11-24
Published online Feb 20, 2017. doi: 10.5493/wjem.v7.i1.11
Table 1 The spectrum of GC-dependent effects on bone-marrow eosinopoiesis
In vivo treatmentBone-marrow effects
Systemic factorsRef.
In vivo bone-marrow EosinophiliaEx vivo effects on response to GM-CSF (CFU counts) in bone-marrow cultureEx vivo effects of challenge on responses to IL-5 or CysLT in bone-marrow cultureGC measurements and interventions targeting GC
TotalEosinophilPrimingMaturation of eosinophils in cultureRegulation of CysLT responsesBlockade by GC targetingPlasma corticosterone
NoneBaselineNANANACompleteNANo effectBaseline[36,52]
Dexamethasone (5-20 mg/kg)Baseline (BALB/c)IncreaseIncreasePrimed by 24 h of injectionIncomplete, rescued by PGE2, anti-α4 integrin antibodyNERU486NA[51,36]
Increased (C57BL/6)IncreaseNENENENERU486N. A.[53]
Surgical traumaIncreased (BALB/c) by 24 h of traumaNENEPrimed by 24 h of traumaCompleteNERU486 MetiraponeStress level by 24 h of trauma[52]
Sensitization and challengeIncreased (BALB/c, B6, BP-2) by 24 h of challengeNo significant increaseIncreased by 24 h of challengePrimed by 24 h of challengeCompleteAttenuated by 24 h of challengeRU486 Metirapone (eosinophilia, priming)Stress level by 24 h of challenge (BALB/c), TNF- induced[22,25,45, 47,50,54,70]
Oral tolerance induction, sensitization and challengeIncrease prevented (BALB/c, BP-2) by 24 h of challengeIncreased by 24 h of challengeIncreased by 24 of challengePriming prevented (BP-2) by 24 h of challengeCompleteNENANE[48]